Malignant Biliary ObstructionNCT03215108
Comparison Between Novel Flower-type Covered Stent and Conventional Covered Stent
A study testing Endoscopic Retrograde CholangioPancreatography(ERCP) in people with Malignant Biliary Obstruction, run by Samsung Medical Center at 1 site in South Korea.
Trial summary
The aim of this animal study is determining the technical feasibility of the novel flower-type covered self-expandable metal stent (F-CSEMS) and investigating whether the novel flower-type covered self-expandable metal stent (F-CSEMS) could prevent cholecystitis and pancreatitis, comparing with conventional covered… Read more about this study
- Who is it for?
- Ages 19 to 85 years
- Conditions the study is for
- Malignant Biliary Obstruction
- What is being tested?
- Endoscopic Retrograde CholangioPancreatography(ERCP)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 256 participants
- Where
- 1 siteSouth Korea
- Study dates
- 12 Jul 2017to 31 Dec 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults from 19 to 85 years of age who have voluntarily agreed to the clinical trial and signed a written agreement
- Patients with malignant extrahepatic bile duct obstruction without surgery
Who cannot join
- Patients who had already undergone surgical biliary drainage
- Patients who previously underwent percutaneous spinal cholecystectomy (PTGBD)
- Patients who underwent conventional metal-on-metal self-expandable metal stents (C-CSEMS)
- Patients who underwent biliary plastic stent implantation for more than 15 days
- Patients with malignant stricture of the intrahepatic bile duct and patients with stenosis within 2 cm of the liver
- Patients whose expected life expectancy is less than 3 months
- Pregnant patient
- Patients who can not undergo endoscopic procedures based on the judgment of the researcher
Trial locations and contacts
1 site in 1 country.
South Korea1 site, 1 recruiting
- Recruiting
SamsungMC
Seoul, KS013
Jae Keun Park, MD, +82-3410-3409, jaekeunjaekeun.park@samsung.com
About this study
Official title: Comparison Between Novel Flower-type Covered Stent and Conventional Covered Stent in Malignant Extrahepatic Biliary Obstruction: Prospective Randomized Multicenter Study
The aim of this animal study is determining the technical feasibility of the novel flower-type covered self-expandable metal stent (F-CSEMS) and investigating whether the novel flower-type covered self-expandable metal stent (F-CSEMS) could prevent cholecystitis and pancreatitis, comparing with conventional covered self-expandable metal stent (C-CSEMS).
Read the detailed description
Covered self-expandable metal stent (C-CSEMS) has the risk of obstruction of the cystic duct, and the main and branch pancreatic ducts due to strong radial force and covering material, which results in cholecystitis and pancreatitis.
A flower-type covered self-expandable metal stent (F-CSEMS) having a five-petal-shaped design with side grooves was constructed to prevent the obstruction of the cystic duct orifice.
This study investigated the value of the F-CSEMS in protection for cholecystitis and pancreatitis.
The investigators will enroll patients with distal MBO (Malignant Biliary Obstruction) who received placement at the Samsung Medical Center. Transpapillary flower-type covered self-expandable metal stent (F-CSEMS) placements will be included in this study.
The diagnosis of MBO will be based on imaging and/or pathological findings. Malignancy was proved by histopathological confirmation obtained by endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA), bile duct biopsy (cytology), pancreatic duct cytology, or liver biopsy.
The investigators will evaluate the frequency of pancreatitis and cholecystitis.
Furthermore, the investigators will evaluate various parameters to clarify the predictive factors of pancreatitis and cholecystitis. The following 10 variables will be evaluated in pancreatitis by univariate analysis: [1] sex, [2] age, [3] primary disease, [4] Covered type (partially or fully), [5] SEMS with high AF, [6] F-CSEMS with high RF, [7] EST before F-CSEMS, [8] previous biliary stent, [9] contrast injection into the pancreatic duct (pancreatogram), and [10] the position of the distal stent edge.
The following 11 variables will be evaluated in cholecystitis by univariate analysis: [1] sex, [2] age, [3] regions of stricture, [4] F-CSEMS with high AF AF (axial force), [5] F-CSEMS with high RF, [6] previous biliary stent, [7] gallbladder stone, [8] contrast injection into the gallbladder (GB injection), [9] involvement to the orifice of the cystic duct (OCD), [10] position of distal stent edge, and [11] cystic duct occlusion by F-CSEMS.
--------------------------------------------------------------------------------------------------------
software: nQuery + nTerim (version 4.0)
- One-sided Chi-square test for proportion comparison
H0: p1=p2 vs H1: p1>p2 (The incidence of complications in the flower-type covered stent is smaller than in the conventional stent.)
p1 = incident rate of complication in full covered stent group p2 = incident rate of complication in flower-type covered stent group
- Set p1(incident rate of complication in full covered stent group) = 15% = 0.15
- expected % decrement in incidence rate = 40%, 50%, 60%, 70% --> p2 = 0.09, 0.075, 0.06, 0.045
- Significance level (alpha) = 0.05
- Maximum number of patients who can be enrolled = 10 per month at SMC = 120 per year
- Expected enroll period = 1 year = 12 months
- Sample size calculation with targeted power of 80% Expected % decrement in incidence rate 70% p2 4.5% Required n per group 116 Required total sample size 232 Required enroll period (year) 1.9
- Power calculation with a total sample size of 232 (116 per group) Expected % decrement in incidence rate 40% 50% 60% 70% p2 9.0% 7.5% 6.0% 4.5% Expected power (%) 32 48 64 80
- Minimum % decrement to be detected with power of 80% Planned enroll period (year) 1 1.5 2 2.5 3 Enroll-able n per group 60 90 120 150 180 Enroll-able total sample size 120 180 240 300 360 Minimum % decrement to be detected 93.33% 78.70% 68.70% 62.70% 58.00% Expected p2 1.0% 3.2% 4.7% 5.6% 6.3%
- Conditions
- Malignant Biliary Obstruction
- Being tested
- Endoscopic Retrograde CholangioPancreatography(ERCP)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Endoscopic Retrograde CholangioPancreatography(ERCP)Device
This study is prospective randomized multicenter study by using Endoscopic Retrograde CholangioPancreatography(ERCP). Comparison between Novel flower-type covered stent and Conventional covered stent in malignant extrahepatic biliary obstruction will be conducted after stent insertion by using Endoscopic Retrograde CholangioPancreatography(ERCP).
| Study group | Role | What they receive |
|---|---|---|
| Flower-CSEMS | Experimental | EGIS Flower Biliary Full Covered Stent(Flower-CSEMS), Bile Duct Stent, (S \& G Biotech Co., Ltd.) will be inserted by using Endoscopic Retrograde CholangioPancreatography(ERCP). Receives: Device: Endoscopic Retrograde CholangioPancreatography(ERCP) |
| Conventional-CSEMS | Experimental | Conventional-CSEMS (S \& G Biotech Co., Ltd.) will be inserted by using Endoscopic Retrograde CholangioPancreatography(ERCP). Receives: Device: Endoscopic Retrograde CholangioPancreatography(ERCP) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pancreatitis, Cholecystitis - Occurrence rate : %
The incidence of pancreatitis is calculated using percentiles.
Measured: 3 months after procedure
Pancreatitis, Cholecystitis - Severity
The extent of each side effect is described in the Adverse Reactions Report according to the National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) Rating System version 4.0.
Measured: 3 months after procedure
Secondary outcomes (2)
Stent-related adverse events
Post -ERCP pancreatitis, Severity of pancreatitis, Bleeding, Microperforation
Measured: 6 months after procedure
Stent patency
We followed up the stent patency until the time of patient death or stent occlusion.
Measured: 6 months after procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jul 2017
- Study start12 Jul 2017 (estimated)
- Primary completion1 Jun 2019 (estimated)
- Study completion31 Dec 2019 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Malignant Biliary ObstructionStudies of the same condition, open and under way.
- More trials run by Samsung Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Flower-CSEMS vs. Conventional-CSEMS
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 256 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Samsung Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jong Kyun Lee, MD PhD, Study chair, Samsung Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03215108
- Sponsor's protocol ID
- 2017-03-098-001
- Status last verified
- May 2017
- First submitted
- 26 May 2017
- Last updated
- 12 Jul 2017
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Jul 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison Between Novel Flower-type Covered Stent and Conventional Covered Stent in Malignant Extrahepatic Biliary Obstruction: Prospective Randomized Multicenter Study
- ClinicalTrials.gov ID
- NCT03215108
- Acronym / sponsor ID
- 2017-03-098-001
- Conditions
- Malignant Biliary Obstruction
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 256 participants (estimated)
- Lead sponsor
- Samsung Medical CenterUniversity, hospital or other
- Study start
- 12 Jul 2017 (estimated)
- Primary completion
- 1 Jun 2019 (estimated)
- Study completion
- 31 Dec 2019 (estimated)
- First posted
- 12 Jul 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this animal study is determining the technical feasibility of the novel flower-type covered self-expandable metal stent (F-CSEMS) and investigating whether the novel flower-type covered self-expandable metal stent (F-CSEMS) could prevent cholecystitis and pancreatitis, comparing with conventional covered self-expandable metal stent (C-CSEMS).
Detailed description
Covered self-expandable metal stent (C-CSEMS) has the risk of obstruction of the cystic duct, and the main and branch pancreatic ducts due to strong radial force and covering material, which results in cholecystitis and pancreatitis.
A flower-type covered self-expandable metal stent (F-CSEMS) having a five-petal-shaped design with side grooves was constructed to prevent the obstruction of the cystic duct orifice.
This study investigated the value of the F-CSEMS in protection for cholecystitis and pancreatitis.
The investigators will enroll patients with distal MBO (Malignant Biliary Obstruction) who received placement at the Samsung Medical Center. Transpapillary flower-type covered self-expandable metal stent (F-CSEMS) placements will be included in this study.
The diagnosis of MBO will be based on imaging and/or pathological findings. Malignancy was proved by histopathological confirmation obtained by endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA), bile duct biopsy (cytology), pancreatic duct cytology, or liver biopsy.
The investigators will evaluate the frequency of pancreatitis and cholecystitis.
Furthermore, the investigators will evaluate various parameters to clarify the predictive factors of pancreatitis and cholecystitis. The following 10 variables will be evaluated in pancreatitis by univariate analysis: [1] sex, [2] age, [3] primary disease, [4] Covered type (partially or fully), [5] SEMS with high AF, [6] F-CSEMS with high RF, [7] EST before F-CSEMS, [8] previous biliary stent, [9] contrast injection into the pancreatic duct (pancreatogram), and [10] the position of the distal stent edge.
The following 11 variables will be evaluated in cholecystitis by univariate analysis: [1] sex, [2] age, [3] regions of stricture, [4] F-CSEMS with high AF AF (axial force), [5] F-CSEMS with high RF, [6] previous biliary stent, [7] gallbladder stone, [8] contrast injection into the gallbladder (GB injection), [9] involvement to the orifice of the cystic duct (OCD), [10] position of distal stent edge, and [11] cystic duct occlusion by F-CSEMS.
--------------------------------------------------------------------------------------------------------
software: nQuery + nTerim (version 4.0)
- One-sided Chi-square test for proportion comparison
H0: p1=p2 vs H1: p1>p2 (The incidence of complications in the flower-type covered stent is smaller than in the conventional stent.)
p1 = incident rate of complication in full covered stent group p2 = incident rate of complication in flower-type covered stent group
- Set p1(incident rate of complication in full covered stent group) = 15% = 0.15
- expected % decrement in incidence rate = 40%, 50%, 60%, 70% --> p2 = 0.09, 0.075, 0.06, 0.045
- Significance level (alpha) = 0.05
- Maximum number of patients who can be enrolled = 10 per month at SMC = 120 per year
- Expected enroll period = 1 year = 12 months
- Sample size calculation with targeted power of 80% Expected % decrement in incidence rate 70% p2 4.5% Required n per group 116 Required total sample size 232 Required enroll period (year) 1.9
- Power calculation with a total sample size of 232 (116 per group) Expected % decrement in incidence rate 40% 50% 60% 70% p2 9.0% 7.5% 6.0% 4.5% Expected power (%) 32 48 64 80
- Minimum % decrement to be detected with power of 80% Planned enroll period (year) 1 1.5 2 2.5 3 Enroll-able n per group 60 90 120 150 180 Enroll-able total sample size 120 180 240 300 360 Minimum % decrement to be detected 93.33% 78.70% 68.70% 62.70% 58.00% Expected p2 1.0% 3.2% 4.7% 5.6% 6.3%
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- Flower-CSEMS vs. Conventional-CSEMS
| Arm | Type | Receives |
|---|---|---|
| Flower-CSEMS | Experimental | Device: Endoscopic Retrograde CholangioPancreatography(ERCP)EGIS Flower Biliary Full Covered Stent(Flower-CSEMS), Bile Duct Stent, (S \& G Biotech Co., Ltd.) will be inserted by using Endoscopic Retrograde CholangioPancreatography(ERCP). |
| Conventional-CSEMS | Experimental | Device: Endoscopic Retrograde CholangioPancreatography(ERCP)Conventional-CSEMS (S \& G Biotech Co., Ltd.) will be inserted by using Endoscopic Retrograde CholangioPancreatography(ERCP). |
Who may qualify
- Ages
- 19 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Adults from 19 to 85 years of age who have voluntarily agreed to the clinical trial and signed a written agreement
- Patients with malignant extrahepatic bile duct obstruction without surgery
Key exclusion criteria (8 listed)
- Patients who had already undergone surgical biliary drainage
- Patients who previously underwent percutaneous spinal cholecystectomy (PTGBD)
- Patients who underwent conventional metal-on-metal self-expandable metal stents (C-CSEMS)
- Patients who underwent biliary plastic stent implantation for more than 15 days
- Patients with malignant stricture of the intrahepatic bile duct and patients with stenosis within 2 cm of the liver
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Endoscopic Retrograde CholangioPancreatography(ERCP)This study is prospective randomized multicenter study by using Endoscopic Retrograde CholangioPancreatography(ERCP). Comparison between Novel flower-type covered stent and Conventional covered stent in malignant extrahepatic biliary obstruction will be conducted after stent insertion by using Endoscopic Retrograde CholangioPancreatography(ERCP). | Device | Conventional-CSEMS, Flower-CSEMS |
Primary outcome
Pancreatitis, Cholecystitis - Occurrence rate : %
Time frame: 3 months after procedure
The incidence of pancreatitis is calculated using percentiles.
Pancreatitis, Cholecystitis - Severity
Time frame: 3 months after procedure
The extent of each side effect is described in the Adverse Reactions Report according to the National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) Rating System version 4.0.
2 secondary outcomes
Stent-related adverse events
Time frame: 6 months after procedure
Stent patency
Time frame: 6 months after procedure
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jul 2017.
- Individual participant dataSharing planned: No
Related trials for Malignant Biliary Obstruction
Active, not recruitingObservational study
A Quality of Life Study in Patients Undergoing Percutaneous Biliary Drainage
Malignant Biliary Obstruction
Recruiting
Suprapapillary Metal Stent vs. Routine Transpapillary Drainage in Malignant Hilar Biliary Obstruction (SMART-B Trial)
Cholangiocarcinoma, Bile Duct Neoplasms
Recruiting
Endoscopic Ultrasound Guided Hepaticogastrostomy With or Without Antegrade Stenting for Palliation of Malignant Distal Biliary Obstruction: Randomized Controlled Trial
Malignant Biliary Obstruction, Malignant Biliary Stricture
Not yet recruiting
Suprapapillary Versus Transpapillary Plastic Stents for Unresectable Malignant Hilar Biliary Obstruction
Biliary Tract Neoplasms, Biliary Drainage
Active, not recruiting
Treatment of Distal Malignant Biliary Obstruction by Uncovered, Partially Covered, or Fully Covered Metal Stents
Pancreatic Cancer Non-resectable, Bile Duct Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jong Kyun Lee, MD PhD study chair
Samsung Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Endoscopic Retrograde CholangioPancreatography(ERCP) in people with Malignant Biliary Obstruction, run by Samsung Medical Center at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 12 Jul 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Jong Kyun Lee, MD PhD (+82-2-3410-3409, jongk.lee@samsung.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pancreatitis, Cholecystitis - Occurrence rate : % (time frame: 3 months after procedure). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jul 2017.